- Home
- SNY vs NEA Comparison
SNY vs NEA Comparison
Compare SNY & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- NEA
- Stock Information
- Founded
- SNY 1994
- NEA 2002
- Country
- SNY France
- NEA United States
- Employees
- SNY N/A
- NEA N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- NEA Finance/Investors Services
- Sector
- SNY Health Care
- NEA Finance
- Exchange
- SNY Nasdaq
- NEA Nasdaq
- Market Cap
- SNY 123.6B
- NEA N/A
- IPO Year
- SNY N/A
- NEA N/A
- Fundamental
- Price
- SNY $52.76
- NEA $10.81
- Analyst Decision
- SNY Buy
- NEA
- Analyst Count
- SNY 2
- NEA 0
- Target Price
- SNY $62.50
- NEA N/A
- AVG Volume (30 Days)
- SNY 3.6M
- NEA 803.4K
- Earning Date
- SNY 04-24-2025
- NEA 01-01-0001
- Dividend Yield
- SNY 3.05%
- NEA 4.23%
- EPS Growth
- SNY 39.56
- NEA N/A
- EPS
- SNY 5.45
- NEA N/A
- Revenue
- SNY $48,817,552,946.00
- NEA N/A
- Revenue This Year
- SNY $5.35
- NEA N/A
- Revenue Next Year
- SNY $6.69
- NEA N/A
- P/E Ratio
- SNY $9.68
- NEA N/A
- Revenue Growth
- SNY N/A
- NEA N/A
- 52 Week Low
- SNY $45.80
- NEA $9.20
- 52 Week High
- SNY $60.12
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- SNY 49.08
- NEA 46.92
- Support Level
- SNY $52.23
- NEA $10.53
- Resistance Level
- SNY $53.70
- NEA $10.78
- Average True Range (ATR)
- SNY 1.34
- NEA 0.19
- MACD
- SNY 0.32
- NEA 0.03
- Stochastic Oscillator
- SNY 84.33
- NEA 96.43
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.